8-K: Avinger Forges Strategic Alliance with Zylox-Tonbridge, Secures $15 Million Funding

Avinger, Inc. has entered into a strategic partnership with Zylox-Tonbridge, including up to $15 million in equity funding, a licensing agreement for the Greater China market, and a technology transfer agreement.

Summary

• Avinger, Inc. has announced a strategic partnership with Zylox-Tonbridge Medical Technology Co., Ltd., a Chinese medical device company.
• The partnership includes up to $15 million in equity funding for Avinger in two tranches.
• The initial $7.5 million investment was priced at $3.66 per share on an as-converted to common stock basis.
• A second tranche of $7.5 million will be funded upon achieving key milestones, including FDA registration of Zylox-Tonbridge as a manufacturer of Avinger products and Avinger achieving $10 million in aggregate revenue over four consecutive quarters.
• Avinger will grant Zylox-Tonbridge exclusive rights to distribute and manufacture Avinger's image-guided devices in the Greater China region.
• Avinger will supply products to Zylox-Tonbridge until their manufacturing capability is established.
• All sales of Avinger products in the Territory will be royalty bearing to Avinger.
• A strategic cooperation framework agreement provides Avinger with the opportunity to distribute certain Zylox-Tonbridge peripheral vascular products in the U.S. and Germany.
• The agreement also allows Avinger to source finished goods from Zylox-Tonbridge after FDA registration of their manufacturing facility.
• CRG Partners exchanged its Series A preferred stock for new Series A-1 preferred stock with a value of $10 million and extended principal payments on Avinger's debt to the first quarter of 2027.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook with a strategic partnership, significant funding, and improved financial terms. The language is optimistic and forward-looking, suggesting a strong positive sentiment from an investment perspective.

Positives

• The partnership provides Avinger with access to the large and growing Greater China market.
• The technology transfer agreement will help build a more cost-efficient manufacturing structure.
• Avinger has the potential to access Zylox-Tonbridge's high-quality peripheral products for distribution in the U.S. and Germany.
• The balance sheet has been significantly improved with a cash infusion and the deferral of principal payments on existing debt.
• The transaction provides the opportunity for new revenue growth and increased sales productivity.

Negatives

• Avinger's obligation to accept conversion of the initial shares of preferred stock and issue and sell shares of preferred stock upon completion of the milestones are each subject to receipt of the approval of Avinger's stockholders.

Risks

• The second tranche of funding is contingent upon achieving key milestones, including FDA registration of Zylox-Tonbridge as a manufacturer and Avinger achieving $10 million in aggregate revenue over four consecutive quarters.
• The success of the partnership depends on the ability of Zylox-Tonbridge to effectively distribute and manufacture Avinger's products in the Greater China region.
• The potential distribution of Zylox-Tonbridge products in the U.S. and Germany is subject to further agreements and regulatory approvals.

Future Outlook

Avinger is positioned to access new growth opportunities in China, improve its operating cost structure, and potentially distribute Zylox-Tonbridge products in the U.S. and Germany. The company is also preparing its image-guided coronary CTO-crossing device for IDE submission later this year.

Management Comments

• Jeff Soinski, Avingers President and CEO, stated that the partnership creates a new pathway for Avinger products to enter the Greater China market and provides the opportunity for a more cost-efficient manufacturing structure.
• Dr. Jonathon Zhao, Chairman and CEO of Zylox-Tonbridge, expressed pleasure in partnering with Avinger to provide Chinese healthcare professionals and patients with cutting-edge medical technologies and disruptive innovative products.
• Mr. Soinski also noted that the transaction has significantly improved Avinger's balance sheet and positioned the company for new growth opportunities.

Industry Context

This announcement reflects a trend of medical device companies seeking strategic partnerships to expand into international markets, particularly China, and to leverage cost-efficient manufacturing capabilities. It also highlights the increasing importance of image-guided technologies in the treatment of vascular disease.

Comparison to Industry Standards

• The strategic partnership between Avinger and Zylox-Tonbridge is similar to other collaborations in the medical device industry where companies seek to leverage each other's strengths in different geographic markets.
• The equity funding agreement is a common method for companies to raise capital for growth and expansion.
• The technology transfer agreement is a strategic move to reduce manufacturing costs and improve supply chain efficiency, similar to other companies that have established manufacturing partnerships in China.
• The licensing agreement is a typical approach for companies to enter new markets, particularly in regulated industries like medical devices.
• The extension of debt terms is a common strategy for companies to improve their financial position and manage cash flow.

Management Changes

Related Party Transactions

• The strategic partnership with Zylox-Tonbridge involves a licensing agreement, technology transfer agreement, and a strategic collaboration agreement.
• The equity funding agreement involves the purchase of preferred and common stock by Zylox-Tonbridge.
• CRG Partners exchanged its Series A preferred stock for new Series A-1 preferred stock and extended principal payments on Avinger's debt.

Stakeholder Impact

• Shareholders: The strategic partnership and funding agreement are expected to improve the company's financial position and growth prospects, potentially increasing shareholder value.
• Employees: The partnership may create new opportunities for employees in manufacturing, sales, and marketing.
• Customers: The partnership may lead to increased access to Avinger's products in the Greater China region and potentially new product offerings in the U.S. and Germany.
• Suppliers: The technology transfer agreement may lead to new manufacturing partnerships and supply chain opportunities.
• Creditors: The deferral of principal payments on existing debt provides Avinger with more financial flexibility.

Next Steps

• Avinger will work with Zylox-Tonbridge to register Avinger products in the Greater China region.
• Avinger will supply products to Zylox-Tonbridge until their manufacturing capability is established.
• Avinger will explore the distribution of Zylox-Tonbridge peripheral vascular products in the U.S. and Germany.
• Avinger will continue to drive sales of its commercial peripheral products and prepare its coronary CTO-crossing device for IDE submission.

Key Dates

Keywords

strategic partnership, equity funding, licensing agreement, technology transfer, Greater China, peripheral vascular, medical devices, manufacturing, distribution, FDA registration